Product Profiles: COPD – Novel combinations race to the finish

Published by: Datamonitor

Published: May. 18, 2012 - 129 Pages


Table of Contents

Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET DEFINITION AND OVERVIEW
Market definition
Product overview
MARKETED PRODUCT PROFILES
Advair (fluticasone/salmeterol; GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Spiriva (tiotropium; Boehringer Ingelheim)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Symbicort (budesonide/formoterol; AstraZeneca)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Daliresp (roflumilast; Takeda)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Arcapta Neohaler (QAB149, indacaterol; Novartis)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Other marketed drugs for COPD
Combivent (salbutamol/ipratropium; Boehringer Ingelheim)
PIPELINE PRODUCT PROFILES
Eklira (aclidinium; Almirall)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Relovair (fluticasone furoate/vilanterol; GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
GSK573719/vilanterol (GlaxoSmithKline/Theravance)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial assessment
QVA149 (indacaterol/glycopyrronium bromide; Novartis)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial assessment
Olodaterol/tiotropium (Boehringer Ingelheim)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial assessment
PT003 (formoterol/glycopyrrolate; Pearl Therapeutics)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other pipeline candidates for COPD
Seebri Breezhaler (glycopyrronium bromide; Sosei/Novartis)
Vilanterol (GlaxoSmithKline)
GSK573719 (GlaxoSmithKline)
LAS40464 (aclidinium/formoterol; Almirall)
QMF149 (mometasone/indacaterol; Novartis)
BIBLIOGRAPHY
Journal papers
Websites
APPENDIX
Contributing experts
Conferences attended
Datamonitor drug assessment scorecard methodology

Abstract

Introduction

COPD is a growing market with a dynamic pipeline aiming to address unmet needs. A number of pipeline products threaten established drug classes. Once-daily bronchodilator combinations in particular are expected to offer a novel treatment option with high clinical and commercial potential and a number of companies are racing to be the first to reach the market.

Features and benefits
  • Access Datamonitor’s independent clinical and commercial assessment of marketed brands and key pipeline agents for COPD.
  • Understand what it takes to differentiate a product in COPD treatment and how the pipeline threatens current market leaders.
  • Assess how pipeline products compare to each other and how they will compete with established therapies.
  • Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
Highlights

As the first once-daily LAMA, Spiriva (tiotropium; Boehringer Ingelheim) has become the clear gold-standard monotherapy for COPD, with widespread use across all disease severities. A number of novel LAMAs are being developed, but these will struggle to compete with Spiriva, which has had years to develop a loyal physician and patient base.Significant developments are expected during 2012 as numerous promising candidates are close to reaching the COPD market. Almirall’s LAMA Eklira (aclidinium) is under review in the US and EU with a decision expected later in 2012. If successful, Eklira could pose the first direct threat to Spiriva (tiotropium; Boehringer Ingelheim).GlaxoSmithKline and Novartis are set to go head-to-head in a number of key drug classes for COPD, including the first once-daily ICS/LABA and LABA/LAMA combinations. With Phase III trials complete and plans to file in mid-2012, GlaxoSmithKline’s Relovair (fluticasone furoate/vilanterol) is on track to become the first approved once-daily ICS/LABA.

Your key questions answered
  • How do marketed treatments of COPD compare to one another and where will pipeline agents fit in?
  • How are key players like Boehringer Ingelheim and GlaxoSmithKline protecting their market position in the face of increasing competition?
  • Which pipeline products will need to compete with currently established treatments, and which can be positioned as add-on therapies?
  • How is COPD treatment expected to change as novel therapies move through the pipeline?


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.